Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genzyme 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genzyme 4Q

Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme

4Q Revenues: $1.2 billion (+13%)

4Q Earnings: $86.7 million (+10%)

FY Revenues: $4.6 billion (+21%)

FY Earnings: $421.1 million (-12%)

Comments: Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%). Aldurazyme sales were $38 million in the quarter (+9%) and $152 million for the year (+23%). Revenue from the Cardiometabolic and Renal segment was $956 million in 2008 (+15%). Sales of sevelamer were $169 million in the quarter (+2%) and $678 million for the year (+13%). Sales of Thyrogen were up 20% in the quarter to $37 million and up 31% for the year to $149 million. For the year, hematologic oncology segment revenue was up 52% to $117 million, and in the quarter was $36 million (+59%). In the quarter, the FDA approved Mozobil for autologous stem cell transplants in non-Hodgkin’s lymphoma and multiple myeloma patients. EU approval is expected in the first half of this year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters